Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Daily

Download Data

Icosavax Inc Price to Earnings Ratio (P/E) on February 29, 2024

Icosavax Inc Price to Earnings Ratio (P/E) is NA on February 29, 2024, a NA change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.

Icosavax Inc 52-week high Price to Earnings Ratio (P/E) is -2.17 on April 20, 2023, which is NA below the current Price to Earnings Ratio (P/E).
Icosavax Inc 52-week low Price to Earnings Ratio (P/E) is -3,599.38 on August 11, 2023, which is NA below the current Price to Earnings Ratio (P/E).
Icosavax Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -34.80.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends